Michael David Curley

Title: Michael David Curley: Innovator in Cancer Treatment

Introduction

Michael David Curley is a prominent inventor based in Cambridge, MA (US). He has made significant contributions to the field of cancer treatment through his innovative work on chimeric antigen receptors. With a total of 2 patents to his name, Curley is recognized for his advancements in targeted therapies.

Latest Patents

Curley's latest patents include "BCMA chimeric antigen receptors and uses thereof" and "Compositions targeting BCMA and methods of use thereof." The first patent provides a BCMA targeting chimeric antigen receptor (CAR) that includes a BCMA binding region and an intracellular costimulatory domain derived from DAP10. This invention also encompasses engineered immune effector cells, such as NK cells, that utilize these chimeric antigen receptors. The second patent focuses on BCMA binders, including antibodies and CAR constructs that specifically bind to BCMA. These innovations enhance the efficacy of NK cells in targeting and killing cancer cells.

Career Highlights

Throughout his career, Michael David Curley has worked with notable organizations, including Takeda Pharmaceutical Company Limited and the University of Texas System. His work has been instrumental in advancing cancer therapies and improving patient outcomes.

Collaborations

Curley has collaborated with esteemed colleagues, including LeeAnn Talarico and Ertan Eryilmaz. These partnerships have contributed to the development of groundbreaking technologies in the field of immunotherapy.

Conclusion

Michael David Curley is a key figure in the innovation of cancer treatment through his patents and collaborations. His work continues to impact the medical field positively, paving the way for new therapeutic approaches.